This invention relates to the field of anti-aging
drug technology, specifically to the application of
small molecule compounds in the preparation of anti-aging drugs. These
small molecule compounds competitively block the interaction between KDM6A and the vacuolar
ATPase V0 domain
subunit ATP6V0C by targeting a specific
small molecule binding pocket of the
histone demethylase KDM6A, thereby inhibiting the
demethylation activity of KDM6A on
lysine residue 36 of ATP6V0C. These small molecule compounds can effectively downregulate aging-related β-
galactosidase activity, improve
cell cycle arrest, and reverse the senescent
phenotype of
nerve cells induced by the environmental
pollutant GenX, making them particularly suitable for combating
premature aging of
nerve cells induced by perfluorinated and polyfluoroalkyl compounds such as GenX. This technical solution can solve the technical problem of the lack of drugs with clearly defined components, a clear
mechanism of action, stable
efficacy, and the ability to specifically alleviate aging in existing technologies, and has ideal prospects for widespread application.